3-hydroxybutyric acid has been researched along with empagliflozin in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 3 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Astiarraga, B; Baldi, S; Bizzotto, R; Ferrannini, E; Frascerra, S; Heise, T; Mari, A; Muscelli, E; Pieber, TR | 1 |
| Ferrannini, E; Mark, M; Mayoux, E | 1 |
| Cha, BS; Cho, JW; Kang, ES; Kim, JH; Kim, SH; Kim, SR; Lee, BW; Lee, M; Lee, YH | 1 |
| Fukushima, A; Furihata, T; Kakutani, N; Katayama, T; Kinugawa, S; Maekawa, S; Matsumoto, J; Nakano, I; Nambu, H; Obata, Y; Saito, A; Shirakawa, R; Takada, S; Yamanashi, K; Yokota, T | 1 |
| Achenbach, S; Bosch, A; Jung, S; Kannenkeril, D; Kolwelter, J; Ott, C; Pietschner, R; Schiffer, M; Schmieder, RE; Striepe, K | 1 |
| Beusekamp, JC; Boorsma, EM; Connelly, MA; Damman, K; DE-Boer, RA; Dullaart, RPF; VAN-DER-Meer, P; VAN-Veldhuisen, DJ; Voorrips, SN; Voors, AA; Westenbrink, BD | 1 |
3 trial(s) available for 3-hydroxybutyric acid and empagliflozin
| Article | Year |
|---|---|
Shift to Fatty Substrate Utilization in Response to Sodium-Glucose Cotransporter 2 Inhibition in Subjects Without Diabetes and Patients With Type 2 Diabetes.
Topics: 3-Hydroxybutyric Acid; Algorithms; Benzhydryl Compounds; C-Reactive Protein; Carbohydrate Metabolism; Diabetes Mellitus, Type 2; Energy Metabolism; Glucagon; Glucagon-Like Peptide 1; Glucose Intolerance; Glucosides; Glycosuria; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Lipid Metabolism; Lipolysis; Membrane Transport Modulators; Renal Elimination; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Time Factors | 2016 |
Effect of empagliflozin on ketone bodies in patients with stable chronic heart failure.
Topics: 3-Hydroxybutyric Acid; Aged; Benzhydryl Compounds; Biomarkers; Blood Pressure; Chronic Disease; Double-Blind Method; Female; Germany; Glucosides; Heart Failure; Humans; Male; Middle Aged; Prospective Studies; Sodium-Glucose Transporter 2 Inhibitors; Time Factors; Treatment Outcome; Up-Regulation; Vascular Stiffness | 2021 |
Longitudinal Changes in Circulating Ketone Body Levels in Patients With Acute Heart Failure: A Post Hoc Analysis of the EMPA-Response-AHF Trial.
Topics: 3-Hydroxybutyric Acid; Acetoacetates; Acetone; Heart Failure; Humans; Ketone Bodies | 2023 |
3 other study(ies) available for 3-hydroxybutyric acid and empagliflozin
| Article | Year |
|---|---|
CV Protection in the EMPA-REG OUTCOME Trial: A "Thrifty Substrate" Hypothesis.
Topics: 3-Hydroxybutyric Acid; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Glucosides; Heart; Humans; Hypoglycemic Agents; Models, Biological; Research Design; Sodium-Glucose Transporter 2; Sodium-Glucose Transporter 2 Inhibitors; Treatment Outcome | 2016 |
Sodium-glucose cotransporter 2 inhibitors regulate ketone body metabolism via inter-organ crosstalk.
Topics: 3-Hydroxybutyric Acid; Animals; Benzhydryl Compounds; Colon; Endoplasmic Reticulum Stress; Glucosides; Humans; Hydroxymethylglutaryl-CoA Synthase; Hypoglycemic Agents; Insulin; Intestinal Mucosa; Ketone Bodies; Kidney; Kidney Tubules, Proximal; Liver; Mice; Mice, Inbred C57BL; Mice, Obese; Monocarboxylic Acid Transporters; Oxo-Acid-Lyases; Random Allocation; Rats; RNA, Messenger; Sodium-Glucose Transporter 2 Inhibitors | 2019 |
Empagliflozin restores lowered exercise endurance capacity via the activation of skeletal muscle fatty acid oxidation in a murine model of heart failure.
Topics: 3-Hydroxybutyric Acid; Adipose Tissue; Animals; Benzhydryl Compounds; Blood Glucose; Disease Models, Animal; Fatty Acids; Glucosides; Heart Failure; Insulin; Male; Mice; Mice, Inbred C57BL; Mitochondria; Muscle Strength; Muscle, Skeletal; Oxidation-Reduction; Oxidative Phosphorylation; Physical Conditioning, Animal; Physical Endurance; Recovery of Function; Sodium-Glucose Transporter 2 Inhibitors | 2020 |